Abiopharma

Cyanotech Reports Financial Results for the Fourth Quarter and Fiscal Year 2025

FDA approve TAFASITAMAB-CXIX

FDA approve LENACAPAVIR

New Form 11-K - LINDE PLC Filed: 2025-06-20 AccNo: 0001628280-25-032289 Size: 230 KB

New Form 11-K - LINDE PLC Filed: 2025-06-20 AccNo: 0001628280-25-032286 Size: 179 KB

New Form 25-NSE - Kronos Bio, Inc. Filed: 2025-06-20 AccNo: 0001354457-25-000547 Size: 2 KB

Aptevo Therapeutics Announces Closing of $8 Million Offering Priced At-the-Market Under Nasdaq Rules

New Form 4 - Verastem, Inc. Filed: 2025-06-20 AccNo: 0001104659-25-061041 Size: 5 KB

FDA approve LENACAPAVIR

New Form 4 - Verastem, Inc. Filed: 2025-06-20 AccNo: 0001104659-25-061040 Size: 4 KB

New Form 4 - Verastem, Inc. Filed: 2025-06-20 AccNo: 0001104659-25-061039 Size: 4 KB

General Announcement::USE OF PROCEEDS FROM THE RIGHTS ISSUE

New Form SC 14D9/A - Kronos Bio, Inc. Filed: 2025-06-20 AccNo: 0001213900-25-055919 Size: 36 KB

New Form 8-K - Kronos Bio, Inc. Filed: 2025-06-20 AccNo: 0001213900-25-055915 Size: 397 KB Item 2.01: Completion of Acquisition or Disposition of Assets Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Item 3.03: Material Modifications to Rights of Security Holders …

New Form SC TO-T/A - Kronos Bio, Inc. Filed: 2025-06-20 AccNo: 0001140361-25-023074 Size: 180 KB